Growth suppression of human oral cancer cells by candidate agents for cetuximab-side effects.
Exp Cell Res
; 376(2): 210-220, 2019 03 15.
Article
em En
| MEDLINE
| ID: mdl-30690028
ABSTRACT
Cetuximab, an inhibitor of the epidermal growth factor receptor that is used widely to treat human cancers including oral squamous cell carcinoma (OSCC), has characteristic side effects of skin rash and hypomagnesemia. However, the mechanisms of and therapeutic agents for skin rashes and hypomagnesemia are still poorly understood. Our gene expression profiling analyses showed that cetuximab activates the p38 MAPK pathways in human skin cells (human keratinocyte cell line [HaCaT]) and inhibits c-Fos-related signals in human embryonic kidney cells (HEK293). We found that while the p38 inhibitor SB203580 inhibited the expression of p38 MAPK targets in HaCaT cells, flavagline reactivated c-Fos-related factors in HEK293 cells. It is noteworthy that, in addition to not interfering with the effect of cetuximab by both compounds, flavagline has additive effect for OSCC growth inhibition in vivo. Collectively, our results indicate that combination of cetuximab and these potential therapeutic agents for cetuximab-related toxicities could be a promising therapeutic strategy for patients with OSCC.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Piridinas
/
Neoplasias Bucais
/
Carcinoma de Células Escamosas
/
Cetuximab
/
Antineoplásicos Imunológicos
/
Inibidores do Crescimento
/
Imidazóis
Tipo de estudo:
Prognostic_studies
Idioma:
En
Revista:
Exp Cell Res
Ano de publicação:
2019
Tipo de documento:
Article